Higher Toxoplasma Gondii Seropositivity in COVID-19 and Tuberculosis Patients: A Case-Control Study
DOI:
https://doi.org/10.47363/JPR/2023(5)159Keywords:
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Vaccine, Coronavirus Disease 2019 (COVID-19), Toxoplasma Gondii, TuberculosisAbstract
Using a case-control study, we compared the antibody-positive profiles for Toxoplasma gondii in patients infected with SARS-CoV-2, tuberculosis (TB), HBV, and HIV-1 in Wuxi of China. As an important pathogen, Toxoplasma gondii has higher co-infection and reactivation rates in patients with SARSCoV-2 and TB infection.
Downloads
Published
2023-07-05
Issue
Section
Articles